Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is a biotechnology company focused on developing and commercializing innovative therapies in critical care and infectious disease. The company commercializes a portfolio of medicines, which include the first and only antibiotic developed specifically to treat Acinetobacter pathogens in adults; an antibiotic therapy for complicated intra-abdominal infections in adults; and a vasopressor indicated to increase blood pressure in adults with septic or other distributive shock. Our Phase 3 development pipeline includes a novel treatment for uncomplicated gonorrhea in adults, managed by our partner, the Global Antibiotics Development Partnership (GARDP). For more information, visit www.innovivaspecialtytherapeutics.com.